Monthly Archives: June 2017

 Biopharmaceutical News Week # 24.2017

                Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation, jcm@btobioinnovation.com       Mergers, Acquisitions and Joint Ventures   JSR Life Sciences (Tokyo, Japan) acquires Selexis (Geneva, Switzerland) a cell-line development company and integrates it with KBI Biopharma, a US contract development and manufacturing organization. Selexis’ SUREtechnology Platform™ can be used […]

read more

Biopharmaceutical News Week # 23.2017

      Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation, jcm@btobioinnovation.com   Business   Grünenthal (Aachen, Germany) in-licenses exclusive global rights (except Japan) of AstraZeneca’s Zomig, or zolmitriptan, for the treatment of migraines and cluster headaches. Under the terms of the agreement, Grünenthal will make a $200 million upfront payment and up to $120 million in various […]

read more

Biopharmaceutical News Week # 22.2017

      Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation, jcm@btobioinnovation.com           Manchester, London, Egypt, Manilla. Coward terrorist attacks once again. We are mourning with our friends and readers around the globe.       Special Report       Highlights from the Meeting A combination of Merck’s Keytruda, a PD-1 checkpoint inhibitor, […]

read more

Biopharmaceutical News Week # 21.2017

NOT ISSUED

read more